MARKET

SLS

SLS

Sellas Life Sciences Group Inc
NASDAQ
2.600
+0.210
+8.79%
After Hours: 2.650 +0.05 +1.92% 18:44 12/01 EST
OPEN
2.420
PREV CLOSE
2.390
HIGH
2.680
LOW
2.340
VOLUME
390.22K
TURNOVER
0
52 WEEK HIGH
7.40
52 WEEK LOW
1.770
MARKET CAP
53.53M
P/E (TTM)
-1.1687
1D
5D
1M
3M
1Y
5Y
SELLAS Life Sciences' CDK9 Inhibitor GFH009 Demonstrates Tumor Growth Inhibition In Small Cell Lung Cancer Murine Model
Benzinga · 16h ago
SELLAS Life Sciences to Participate in the JMP Securities Hematology and Oncology Summit
NEW YORK, Nov. 30, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, t...
GlobeNewswire · 1d ago
SELLAS Life Sciences Group Third Quarter 2022 Earnings: US$0.34 loss per share (vs US$0.45 loss in 3Q 2021)
SELLAS Life Sciences Group ( NASDAQ:SLS ) Third Quarter 2022 Results Key Financial Results Net loss: US$7.02m (flat on...
Simply Wall St. · 11/16 10:28
Alliance Global Partners Maintains Buy on SELLAS Life Sciences Gr, Lowers Price Target to $8
Benzinga · 11/15 13:08
Why Infinity Pharmaceuticals Shares Tumbled Around 38%; Here Are 79 Biggest Movers From Yesterday
Benzinga · 11/15 10:19
Dow Surges 150 Points; Crude Oil Falls Sharply
Benzinga · 11/14 19:34
SELLAS Life Sciences Shares Tumble As Acute Myeloid Leukemia Trial Will Longer Than Anticipated
Benzinga · 11/14 18:25
BRIEF-Sellas Life Sciences Provides Business Update And Reports Q3 Financial Results
Reuters · 11/14 18:20
More
About SLS
SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing cancer immunotherapeutics for a range of cancer indications. The Company's product candidates include galinpepimut-S (GPS) and nelipepimut-S (NPS). Its lead product candidate, GPS, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center (MSK) that targets the Wilms tumor 1 (WT1) protein, which is present in 20 or more cancer types. GPS has potential both as a monotherapy and in combination to address a range of hematologic malignancies and solid tumor indications. Its second product candidate, NPS, is a cancer immunotherapy targeting the human epidermal growth factor receptor 2 (HER2), which is expressing cancers with potential for the treatment of patients with early-stage breast cancer with low to intermediate HER2 expression, which includes triple negative breast cancer (TNBC) patients.

Webull offers kinds of Sellas Life Sciences Group Inc stock information, including NASDAQ:SLS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLS stock methods without spending real money on the virtual paper trading platform.